Skip to main content
Fig. 6 | Radiation Oncology

Fig. 6

From: Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer

Fig. 6

Clinical pharmacokinetics of AT-101. AT-101 concentration was measured by HPLC in patient plasma samples collected at 30 min, 1, 2, 3, 4, 5, 6, 7, 8 and 24 h after oral intake of AT-101. Pharmacokinetic profiles are shown for the AT-101 dose levels of 10 mg (n = 13) and 20 mg (n = 1). Data represent mean values ± SD

Back to article page